粪菌移植调控肠道菌群失调的风险和收益(综述)
创作:fang fang 审核:迟卉 02月04日
  • 粪菌移植(FMT)是治疗艰难梭状菌感染(CDI)的有效方法,而对过敏性疾病、炎症性肠病和自身免疫性疾病的疗效有待证实;
  • FMT通过纠正肠道菌群失衡,恢复菌群构成及功能实现对疾病的防治,在哮喘等动物模型中证实有效;
  • 除CDI外,菌群变化与疾病之间的因果关系及机制并不明确,FMT时间和剂量难以确定,亦存在接触有害菌株、感染传染病等风险;
  • 需进一步研究明确FMT功效,制定个体化供-受体配对方案,保证安全、稳定的治疗。
主编推荐语
迟卉
粪菌移植(FMT)对艰难梭菌感染(CDI)治疗的安全有效性现已在多数国家得到认可,并鲜有不良反应事件报道。但FMT对于其他疾病治疗的风险收益率仍存在争议。Allergy: European Journal of Allergy and Clinical Immunology近期发表文章,探讨在免疫介导性疾病中支持和反对FMT的论点。文章指出,FMT确实是一种很有前途的治疗方法,在可通过调节肠道菌群为靶点改善病理生理的疾病中贡献显著,但是在部分慢性疾病中由于造成失调的驱动因素、时间及其因果关系尚不明确,使用FMT的合理性因此降低,且风险与收益的比率并不理想。 除此之外,文章指出在关于免疫介导性疾病中使用FMT的研究中目前仍存在的空白,并就如何在未来的研究中填补这些研究空白提出了建议,值得相关研究人员关注。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!

Pros and Cons: Is Fecal Microbiota Transplantation a safe and efficient treatment option for gut dysbiosis?

利与弊:粪菌移植对于肠道菌群失调是一种安全有效的治疗方案吗?

10.1111/all.14750

01-23, Other

Abstract & Authors:展开

Abstract:收起
Fecal Microbiota Transplantation (FMT) is wellestablished as an effective treatment for Clostridioides difficile infection (CDI), restoring gut microbiome diversity and function. The utility of FMTiscurrently being explored in relation to other immune-mediatedpathologies, such as Allergic Disease, Inflammatory Bowel Diseases and Autoimmune Diseases. Clinical trials in these areas are ongoing, and the altered gut microbiota (dysbiosis) that is often observed in these pathologies provides arationale forthe application ofFMT to restore the microbiome. However, there is controversy on the risk-benefit ratio as it relates to the use of FMTs in pathologies other than CDI. In this Pro and Con article, we present the arguments for and against the use of FMT in immune-mediated pathologies, such as Allergic Disease. We further identify research gaps and recommend how these may be addressed in future studies.

First Authors:
Tom Marrs

Correspondence Authors:
Tom Marrs

All Authors:
Tom Marrs,Jens Walter

评论